🔗 Share this article Social Media Content Creators Fueling Parallel Market for Unapproved Slimming Medication A shadow economy for unapproved weight-loss medications is being driven by TikTok fitness influencers and vendors on communication apps, based on recent findings. Experimental Treatment Gaining Popularity Via Social Media The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged fat-burning properties. Followers are encouraged to contact these accounts privately for source information, while also obtaining discount codes. Active Commerce on Messaging Platforms Separately, a flourishing market exists on messaging services, where groups with numerous of participants share comparison photos, injection guides and claims of next-day UK delivery. Vendors promote the drug there before directing customers to other platforms for transactions. Understanding The Experimental Drug Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could help individuals reduce up to 25% of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic. Healthcare Experts Express Concerns Nevertheless, doctors and pharmacists have warned that the sale of what remains an unapproved drug in the United Kingdom is a cause for concern and could lead to individuals administering substances of uncertain source. Some professionals stated the demand for retatrutide could be connected to the rising cost of licensed slimming treatments such as Mounjaro. Legal Status and Implementation Selling the unapproved drug on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012. Several content creators try to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and supply can still violate pharmaceutical, advertising, and consumer regulations, risking penalties, prosecution or prison. Service Reaction and Content Removal According to the social media company, the service has taken down problematic material and banned associated hashtags and query recommendations. The company stated it was dedicated to keeping the service safe and investing in strengthening compliance measures. Digital Trading Operations Investigations also discovered groups with up to 9,000 members selling retatrutide using Telegram's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” instantly brings up channels with thousands of users, populated with photos of weight loss, glowing testimonials and step-by-step instructions for preparing or administering at residence. Within minutes of entering one group, a vendor posted WhatsApp details, where the majority of transactions occur. The vendor sent an guidebook and promised shipping within two days. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None inquired about weight, medical conditions or previous experience. Product Details and Pricing Within these groups, posts display black plastic parcels with postal service labels, stating to include new batches. One message read: “It took eight of us to load them this morning.” Buyers can select between powder vials, mixed at home with purified liquid, or ready-to-use pens usually sold at 160 pounds for 20mg. When asked how long a injector should be used, vendors give contradictory responses ranging from a few weeks to “depends on your body”. Platform Moderation and Security Actions A representative for the messaging service said it regularly monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”. Healthcare Expert Warnings “People are injecting materials they can’t verify. Even if the science behind retatrutide is valid, these online products may not contain what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U. Dr Crystal Wyllie of Asda Online Doctor connected the surge in interest to recent cost increases for approved slimming drugs such as Mounjaro. “With costs increasing, individuals are using online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she explained. Her staff has already seen patients harmed by self-injection from unconfirmed suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your well-being,” stated Wyllie. “These materials could be impure or incorrectly dosed.” Producer Position A spokesperson from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may expose patients to potentially significant health risks”.